Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026. Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.…
Niki BioSolutions Announces Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 Conference
Niki BioSolutions (NASDAQ: NIKI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 1.570 USD on 20 November 2026, down 88.9% over 52 weeks. Its 52-week range is 1.415 USD to 17.20 USD: the price is 90.9% below the high and 11.0% above the low.
Its market capitalisation is 4.90M USD.
Niki BioSolutions reports return on equity of -5.9% and an operating margin of 0.0%.
Its debt exceeds its cash by 1.67M USD, a debt-to-equity ratio of 0.15. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.